Cell Therapeutics, Inc. - Product Pipeline Review - 2014

Global Markets Direct
April 30, 2014
62 Pages - GMD12097
$1,500.00

Summary

Global Markets Direct’s, ‘Cell Therapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the Cell Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cell Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cell Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cell Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Cell Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Cell Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cell Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cell Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cell Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cell Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cell Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

'

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cell Therapeutics, Inc. Snapshot 5
Cell Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Cell Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Cell Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Cell Therapeutics, Inc. - Pipeline Products Glance 13
Cell Therapeutics, Inc. - Late Stage Pipeline Products 13
Filing rejected/Withdrawn Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Cell Therapeutics, Inc. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Cell Therapeutics, Inc. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Cell Therapeutics, Inc. - Drug Profiles 18
paclitaxel poliglumex 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
pixantrone dimaleate 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
pacritinib 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
brostallicin 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
lisofylline 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CT-1578 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CT-47463 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Cell Therapeutics, Inc. - Pipeline Analysis 34
Cell Therapeutics, Inc. - Pipeline Products by Target 34
Cell Therapeutics, Inc. - Pipeline Products by Route of Administration 36
Cell Therapeutics, Inc. - Pipeline Products by Molecule Type 37
Cell Therapeutics, Inc. - Pipeline Products by Mechanism of Action 38
Cell Therapeutics, Inc. - Recent Pipeline Updates 40
Cell Therapeutics, Inc. - Dormant Projects 52
Cell Therapeutics, Inc. - Discontinued Pipeline Products 54
Discontinued Pipeline Product Profiles 54
CT-2584 54
nortopixantrone 54
topixantrone 54
Cell Therapeutics, Inc. - Company Statement 55
Cell Therapeutics, Inc. - Locations And Subsidiaries 60
Head Office 60
Other Locations & Subsidiaries 60
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Tables
Cell Therapeutics, Inc., Key Information 5
Cell Therapeutics, Inc., Key Facts 5
Cell Therapeutics, Inc. - Pipeline by Indication, 2014 7
Cell Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Cell Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Cell Therapeutics, Inc. - Partnered Products in Pipeline, 2014 11
Cell Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Cell Therapeutics, Inc. - Filing rejected/Withdrawn, 2014 13
Cell Therapeutics, Inc. - Phase III, 2014 14
Cell Therapeutics, Inc. - Phase II, 2014 15
Cell Therapeutics, Inc. - Phase I, 2014 16
Cell Therapeutics, Inc. - Preclinical, 2014 17
Cell Therapeutics, Inc. - Pipeline by Target, 2014 35
Cell Therapeutics, Inc. - Pipeline by Route of Administration, 2014 36
Cell Therapeutics, Inc. - Pipeline by Molecule Type, 2014 37
Cell Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 39
Cell Therapeutics, Inc. - Recent Pipeline Updates, 2014 40
Cell Therapeutics, Inc. - Dormant Developmental Projects,2014 52
Cell Therapeutics, Inc. - Discontinued Pipeline Products, 2014 54
Cell Therapeutics, Inc., Subsidiaries 60

List of Figures
Cell Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 7
Cell Therapeutics, Inc. - Pipeline by Stage of Development, 2014 9
Cell Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 10
Cell Therapeutics, Inc. - Partnered Products in Pipeline, 2014 11
Cell Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 34
Cell Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 36
Cell Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 37
Cell Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 38

$1,500.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Custom Research

Need a custom report
tailored to your goals and budget? 

E-mail us your project outline
or call Client Services to speak
with your industry analyst.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax

Discount Codes

Request Discount Codes
for reports of interest to you.

info@LMRreports.com
+1 212 564 2838
+1 212 564 8133 fax